Last reviewed · How we verify

fenoldopam infusion — Competitive Intelligence Brief

fenoldopam infusion (fenoldopam infusion) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine-1 receptor agonist. Area: Cardiovascular.

marketed Dopamine-1 receptor agonist Dopamine-1 (DA1) receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

fenoldopam infusion (fenoldopam infusion) — University of Roma La Sapienza. Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
fenoldopam infusion TARGET fenoldopam infusion University of Roma La Sapienza marketed Dopamine-1 receptor agonist Dopamine-1 (DA1) receptor
Fenoldopam mesilate Fenoldopam mesilate IRCCS Policlinico S. Donato marketed Dopamine-1 receptor agonist Dopamine-1 (DA1) receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine-1 receptor agonist class)

  1. IRCCS Policlinico S. Donato · 1 drug in this class
  2. University of Roma La Sapienza · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fenoldopam infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/fenoldopam-infusion. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: